<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Steidl E</submitter><funding>Dr. Senckenberg foundation</funding><funding>Else Kröner-Fresenius-Stiftung</funding><pagination>1956-1965</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8113145</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>48(6)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Perfusion-weighted MRI (PWI) and O-(2-[&lt;sup>18&lt;/sup>F]fluoroethyl-)-l-tyrosine ([&lt;sup>18&lt;/sup>F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [&lt;sup>18&lt;/sup>F]FET PET.&lt;h4>Methods&lt;/h4>We evaluated 104 patients with WHO grade II-IV glioma and suspected TP on conventional MRI using PWI and dynamic [&lt;sup>18&lt;/sup>F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV&lt;sub>max&lt;/sub>) were obtained from dynamic </pubmed_abstract><journal>European journal of nuclear medicine and molecular imaging</journal><pubmed_title>Sequential implementation of DSC-MR perfusion and dynamic [&lt;sup>18&lt;/sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.</pubmed_title><pmcid>PMC8113145</pmcid><funding_grant_id>2014/SIN-02</funding_grant_id><funding_grant_id>Clinican-Scientist Stipend</funding_grant_id><pubmed_authors>Shah NJ</pubmed_authors><pubmed_authors>Polomac N</pubmed_authors><pubmed_authors>Steinbach JP</pubmed_authors><pubmed_authors>Lohmann P</pubmed_authors><pubmed_authors>Filss CP</pubmed_authors><pubmed_authors>Mottaghy FM</pubmed_authors><pubmed_authors>Maurer GD</pubmed_authors><pubmed_authors>Filipski K</pubmed_authors><pubmed_authors>Steidl E</pubmed_authors><pubmed_authors>Hmeidan SA</pubmed_authors><pubmed_authors>Hattingen E</pubmed_authors><pubmed_authors>Langen KJ</pubmed_authors><pubmed_authors>Galldiks N</pubmed_authors><pubmed_authors>Keil F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sequential implementation of DSC-MR perfusion and dynamic [&lt;sup>18&lt;/sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.</name><description>&lt;h4>Purpose&lt;/h4>Perfusion-weighted MRI (PWI) and O-(2-[&lt;sup>18&lt;/sup>F]fluoroethyl-)-l-tyrosine ([&lt;sup>18&lt;/sup>F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [&lt;sup>18&lt;/sup>F]FET PET.&lt;h4>Methods&lt;/h4>We evaluated 104 patients with WHO grade II-IV glioma and suspected TP on conventional MRI using PWI and dynamic [&lt;sup>18&lt;/sup>F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV&lt;sub>max&lt;/sub>) were obtained from dynamic </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-19T16:17:20.765Z</modification><creation>2025-04-19T16:17:20.765Z</creation></dates><accession>S-EPMC8113145</accession><cross_references><pubmed>33241456</pubmed><doi>10.1007/s00259-020-05114-0</doi></cross_references></HashMap>